1 Oral Hypoglycemic Agents (OHAs) Market Overview 1.1 Product Overview and Scope of Oral Hypoglycemic Agents (OHAs) 1.2 Oral Hypoglycemic Agents (OHAs) Segment by Type 1.2.1 Global Oral Hypoglycemic Agents (OHAs) Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 Sulfonylureas 1.2.3 Metformin 1.2.4 Thiazolidinediones 1.2.5 Alpha-Glucosidase Inhibitors 1.3 Oral Hypoglycemic Agents (OHAs) Segment by Application 1.3.1 Oral Hypoglycemic Agents (OHAs) Sales Comparison by Application: (2021-2027) 1.3.2 Type 2 Diabetes Mellitus 1.3.3 Type 1 Diabetes Mellitus 1.4 Global Oral Hypoglycemic Agents (OHAs) Market Size Estimates and Forecasts 1.4.1 Global Oral Hypoglycemic Agents (OHAs) Revenue 2016-2027 1.4.2 Global Oral Hypoglycemic Agents (OHAs) Sales 2016-2027 1.4.3 Oral Hypoglycemic Agents (OHAs) Market Size by Region: 2016 Versus 2021 Versus 2027 2 Oral Hypoglycemic Agents (OHAs) Market Competition by Manufacturers 2.1 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Manufacturers (2016-2021) 2.2 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Oral Hypoglycemic Agents (OHAs) Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Oral Hypoglycemic Agents (OHAs) Manufacturing Sites, Area Served, Product Type 2.5 Oral Hypoglycemic Agents (OHAs) Market Competitive Situation and Trends 2.5.1 Oral Hypoglycemic Agents (OHAs) Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Oral Hypoglycemic Agents (OHAs) Players Market Share by Revenue 2.5.3 Global Oral Hypoglycemic Agents (OHAs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Oral Hypoglycemic Agents (OHAs) Retrospective Market Scenario by Region 3.1 Global Oral Hypoglycemic Agents (OHAs) Retrospective Market Scenario in Revenue by Region: 2016-2021 3.2 Global Oral Hypoglycemic Agents (OHAs) Retrospective Market Scenario in Sales by Region: 2016-2021 3.3 North America Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country 3.3.1 North America Oral Hypoglycemic Agents (OHAs) Sales by Country 3.3.2 North America Oral Hypoglycemic Agents (OHAs) Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country 3.4.1 Europe Oral Hypoglycemic Agents (OHAs) Sales by Country 3.4.2 Europe Oral Hypoglycemic Agents (OHAs) Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Region 3.5.1 Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Region 3.5.2 Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country 3.6.1 Latin America Oral Hypoglycemic Agents (OHAs) Sales by Country 3.6.2 Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country 3.7.1 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Country 3.7.2 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 UAE 4 Global Oral Hypoglycemic Agents (OHAs) Historic Market Analysis by Type 4.1 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2016-2021) 4.2 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2016-2021) 4.3 Global Oral Hypoglycemic Agents (OHAs) Price by Type (2016-2021) 5 Global Oral Hypoglycemic Agents (OHAs) Historic Market Analysis by Application 5.1 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2016-2021) 5.2 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2016-2021) 5.3 Global Oral Hypoglycemic Agents (OHAs) Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Pfizer 6.1.1 Pfizer Corporation Information 6.1.2 Pfizer Description and Business Overview 6.1.3 Pfizer Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Pfizer Product Portfolio 6.1.5 Pfizer Recent Developments/Updates 6.2 GlaxoSmithKline 6.2.1 GlaxoSmithKline Corporation Information 6.2.2 GlaxoSmithKline Description and Business Overview 6.2.3 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2016-2021) 6.2.4 GlaxoSmithKline Product Portfolio 6.2.5 GlaxoSmithKline Recent Developments/Updates 6.3 Bayer 6.3.1 Bayer Corporation Information 6.3.2 Bayer Description and Business Overview 6.3.3 Bayer Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Bayer Product Portfolio 6.3.5 Bayer Recent Developments/Updates 6.4 Bristol-Myers Squibb 6.4.1 Bristol-Myers Squibb Corporation Information 6.4.2 Bristol-Myers Squibb Description and Business Overview 6.4.3 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Bristol-Myers Squibb Product Portfolio 6.4.5 Bristol-Myers Squibb Recent Developments/Updates 6.5 Novonordisk 6.5.1 Novonordisk Corporation Information 6.5.2 Novonordisk Description and Business Overview 6.5.3 Novonordisk Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2016-2021) 6.5.4 Novonordisk Product Portfolio 6.5.5 Novonordisk Recent Developments/Updates 6.6 Sanofi-Aventis 6.6.1 Sanofi-Aventis Corporation Information 6.6.2 Sanofi-Aventis Description and Business Overview 6.6.3 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2016-2021) 6.6.4 Sanofi-Aventis Product Portfolio 6.6.5 Sanofi-Aventis Recent Developments/Updates 6.7 Servier 6.6.1 Servier Corporation Information 6.6.2 Servier Description and Business Overview 6.6.3 Servier Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Servier Product Portfolio 6.7.5 Servier Recent Developments/Updates 6.8 Huadong Medicine 6.8.1 Huadong Medicine Corporation Information 6.8.2 Huadong Medicine Description and Business Overview 6.8.3 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2016-2021) 6.8.4 Huadong Medicine Product Portfolio 6.8.5 Huadong Medicine Recent Developments/Updates 6.9 Wanbang Biopharmaceuticals 6.9.1 Wanbang Biopharmaceuticals Corporation Information 6.9.2 Wanbang Biopharmaceuticals Description and Business Overview 6.9.3 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2016-2021) 6.9.4 Wanbang Biopharmaceuticals Product Portfolio 6.9.5 Wanbang Biopharmaceuticals Recent Developments/Updates 6.10 Double-Crane Pharmaceutical 6.10.1 Double-Crane Pharmaceutical Corporation Information 6.10.2 Double-Crane Pharmaceutical Description and Business Overview 6.10.3 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2016-2021) 6.10.4 Double-Crane Pharmaceutical Product Portfolio 6.10.5 Double-Crane Pharmaceutical Recent Developments/Updates 6.11 Guangzhou Pharmaceutical 6.11.1 Guangzhou Pharmaceutical Corporation Information 6.11.2 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Description and Business Overview 6.11.3 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2016-2021) 6.11.4 Guangzhou Pharmaceutical Product Portfolio 6.11.5 Guangzhou Pharmaceutical Recent Developments/Updates 7 Oral Hypoglycemic Agents (OHAs) Manufacturing Cost Analysis 7.1 Oral Hypoglycemic Agents (OHAs) Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Oral Hypoglycemic Agents (OHAs) 7.4 Oral Hypoglycemic Agents (OHAs) Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Oral Hypoglycemic Agents (OHAs) Distributors List 8.3 Oral Hypoglycemic Agents (OHAs) Customers 9 Oral Hypoglycemic Agents (OHAs) Market Dynamics 9.1 Oral Hypoglycemic Agents (OHAs) Industry Trends 9.2 Oral Hypoglycemic Agents (OHAs) Growth Drivers 9.3 Oral Hypoglycemic Agents (OHAs) Market Challenges 9.4 Oral Hypoglycemic Agents (OHAs) Market Restraints 10 Global Market Forecast 10.1 Oral Hypoglycemic Agents (OHAs) Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Oral Hypoglycemic Agents (OHAs) by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Oral Hypoglycemic Agents (OHAs) by Type (2022-2027) 10.2 Oral Hypoglycemic Agents (OHAs) Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Oral Hypoglycemic Agents (OHAs) by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Oral Hypoglycemic Agents (OHAs) by Application (2022-2027) 10.3 Oral Hypoglycemic Agents (OHAs) Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Oral Hypoglycemic Agents (OHAs) by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Oral Hypoglycemic Agents (OHAs) by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Oral Hypoglycemic Agents (OHAs) Sales (K MT) Growth Rate Comparison by Type (2021-2027) Table 2. Global Oral Hypoglycemic Agents (OHAs) Sales (K MT) Comparison by Application (2021-2027) Table 3. Global Oral Hypoglycemic Agents (OHAs) Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Oral Hypoglycemic Agents (OHAs) Covered in This Study Table 5. Global Oral Hypoglycemic Agents (OHAs) Sales (K MT) of Key Manufacturers (2016-2021) Table 6. Global Oral Hypoglycemic Agents (OHAs) Sales Share by Manufacturers (2016-2021) Table 7. Global Oral Hypoglycemic Agents (OHAs) Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Oral Hypoglycemic Agents (OHAs) Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Oral Hypoglycemic Agents (OHAs) Average Price (USD/MT) of Key Manufacturers (2016-2021) Table 10. Manufacturers Oral Hypoglycemic Agents (OHAs) Manufacturing Sites and Area Served Table 11. Manufacturers Oral Hypoglycemic Agents (OHAs) Product Type Table 12. Global Oral Hypoglycemic Agents (OHAs) Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Oral Hypoglycemic Agents (OHAs) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oral Hypoglycemic Agents (OHAs) as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Oral Hypoglycemic Agents (OHAs) Sales by Region (2016-2021) & (K MT) Table 16. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2016-2021) Table 17. Global Oral Hypoglycemic Agents (OHAs) Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2016-2021) & (K MT) Table 19. North America Oral Hypoglycemic Agents (OHAs) Sales Market Share by Country (2016-2021) Table 20. North America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Country (2016-2021) Table 22. Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2016-2021) & (K MT) Table 23. Europe Oral Hypoglycemic Agents (OHAs) Sales Market Share by Country (2016-2021) Table 24. Europe Oral Hypoglycemic Agents (OHAs) Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Region (2016-2021) & (K MT) Table 27. Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2016-2021) Table 30. Latin America Oral Hypoglycemic Agents (OHAs) Sales by Country (2016-2021) & (K MT) Table 31. Latin America Oral Hypoglycemic Agents (OHAs) Sales Market Share by Country (2016-2021) Table 32. Latin America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Country (2016-2021) & (K MT) Table 35. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Country (2016-2021) Table 38. Global Oral Hypoglycemic Agents (OHAs) Sales (K MT) by Type (2016-2021) Table 39. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2016-2021) Table 40. Global Oral Hypoglycemic Agents (OHAs) Revenue (Million US$) by Type (2016-2021) Table 41. Global Oral Hypoglycemic Agents (OHAs) Revenue Share by Type (2016-2021) Table 42. Global Oral Hypoglycemic Agents (OHAs) Price (USD/MT) by Type (2016-2021) Table 43. Global Oral Hypoglycemic Agents (OHAs) Sales (K MT) by Application (2016-2021) Table 44. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2016-2021) Table 45. Global Oral Hypoglycemic Agents (OHAs) Revenue (Million US$) by Application (2016-2021) Table 46. Global Oral Hypoglycemic Agents (OHAs) Revenue Share by Application (2016-2021) Table 47. Global Oral Hypoglycemic Agents (OHAs) Price (USD/MT) by Application (2016-2021) Table 48. Pfizer Corporation Information Table 49. Pfizer Description and Business Overview Table 50. Pfizer Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 51. Pfizer Oral Hypoglycemic Agents (OHAs) Product Table 52. Pfizer Recent Developments/Updates Table 53. GlaxoSmithKline Corporation Information Table 54. GlaxoSmithKline Description and Business Overview Table 55. GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 56. GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Product Table 57. GlaxoSmithKline Recent Developments/Updates Table 58. Bayer Corporation Information Table 59. Bayer Description and Business Overview Table 60. Bayer Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 61. Bayer Oral Hypoglycemic Agents (OHAs) Product Table 62. Bayer Recent Developments/Updates Table 63. Bristol-Myers Squibb Corporation Information Table 64. Bristol-Myers Squibb Description and Business Overview Table 65. Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 66. Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Product Table 67. Bristol-Myers Squibb Recent Developments/Updates Table 68. Novonordisk Corporation Information Table 69. Novonordisk Description and Business Overview Table 70. Novonordisk Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 71. Novonordisk Oral Hypoglycemic Agents (OHAs) Product Table 72. Novonordisk Recent Developments/Updates Table 73. Sanofi-Aventis Corporation Information Table 74. Sanofi-Aventis Description and Business Overview Table 75. Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 76. Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Product Table 77. Sanofi-Aventis Recent Developments/Updates Table 78. Servier Corporation Information Table 79. Servier Description and Business Overview Table 80. Servier Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 81. Servier Oral Hypoglycemic Agents (OHAs) Product Table 82. Servier Recent Developments/Updates Table 83. Huadong Medicine Corporation Information Table 84. Huadong Medicine Description and Business Overview Table 85. Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 86. Huadong Medicine Oral Hypoglycemic Agents (OHAs) Product Table 87. Huadong Medicine Recent Developments/Updates Table 88. Wanbang Biopharmaceuticals Corporation Information Table 89. Wanbang Biopharmaceuticals Description and Business Overview Table 90. Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 91. Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Product Table 92. Wanbang Biopharmaceuticals Recent Developments/Updates Table 93. Double-Crane Pharmaceutical Corporation Information Table 94. Double-Crane Pharmaceutical Description and Business Overview Table 95. Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 96. Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Table 97. Double-Crane Pharmaceutical Recent Developments/Updates Table 98. Guangzhou Pharmaceutical Corporation Information Table 99. Guangzhou Pharmaceutical Description and Business Overview Table 100. Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 101. Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Table 102. Guangzhou Pharmaceutical Recent Developments/Updates Table 103. Production Base and Market Concentration Rate of Raw Material Table 104. Key Suppliers of Raw Materials Table 105. Oral Hypoglycemic Agents (OHAs) Distributors List Table 106. Oral Hypoglycemic Agents (OHAs) Customers List Table 107. Oral Hypoglycemic Agents (OHAs) Market Trends Table 108. Oral Hypoglycemic Agents (OHAs) Growth Drivers Table 109. Oral Hypoglycemic Agents (OHAs) Market Restraints Table 110. Global Oral Hypoglycemic Agents (OHAs) Sales Forecast by Type (2022-2027) & (K MT) Table 111. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share Forecast by Type (2022-2027) Table 112. Global Oral Hypoglycemic Agents (OHAs) Revenue Forecast by Type (2022-2027) & (US$ Million) Table 113. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share Forecast by Type (2022-2027) Table 114. Global Oral Hypoglycemic Agents (OHAs) Sales Forecast by Application (2022-2027) & (K MT) Table 115. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share Forecast by Application (2022-2027) Table 116. Global Oral Hypoglycemic Agents (OHAs) Revenue Forecast by Application (2022-2027) & (US$ Million) Table 117. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share Forecast by Application (2022-2027) Table 118. Global Oral Hypoglycemic Agents (OHAs) Sales Forecast by Region (2022-2027) & (K MT) Table 119. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share Forecast by Region (2022-2027) Table 120. Global Oral Hypoglycemic Agents (OHAs) Revenue Forecast by Region (2022-2027) & (US$ Million) Table 121. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share Forecast by Region (2022-2027) Table 122. Research Programs/Design for This Report Table 123. Key Data Information from Secondary Sources Table 124. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Oral Hypoglycemic Agents (OHAs) Figure 2. Global Oral Hypoglycemic Agents (OHAs) Market Share by Type in 2020 & 2027 Figure 3. Sulfonylureas Product Picture Figure 4. Metformin Product Picture Figure 5. Thiazolidinediones Product Picture Figure 6. Alpha-Glucosidase Inhibitors Product Picture Figure 7. Global Oral Hypoglycemic Agents (OHAs) Market Share by Application in 2020 & 2027 Figure 8. Type 2 Diabetes Mellitus Figure 9. Type 1 Diabetes Mellitus Figure 10. Global Oral Hypoglycemic Agents (OHAs) Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 11. Global Oral Hypoglycemic Agents (OHAs) Market Size 2016-2027 (US$ Million) Figure 12. Global Oral Hypoglycemic Agents (OHAs) Sales 2016-2027 (K MT) Figure 13. Global Oral Hypoglycemic Agents (OHAs) Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 14. Oral Hypoglycemic Agents (OHAs) Sales Share by Manufacturers in 2020 Figure 15. Global Oral Hypoglycemic Agents (OHAs) Revenue Share by Manufacturers in 2020 Figure 16. The Global 5 and 10 Largest Oral Hypoglycemic Agents (OHAs) Players: Market Share by Revenue in 2020 Figure 17. Oral Hypoglycemic Agents (OHAs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 18. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region (2016-2021) Figure 19. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Region in 2020 Figure 20. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region (2016-2021) Figure 21. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Region in 2020 Figure 22. U.S. Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 23. Canada Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 24. Germany Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 25. France Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. U.K. Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. Italy Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. Russia Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. China Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. Japan Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. South Korea Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. India Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. Australia Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. Taiwan Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. Indonesia Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Thailand Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Malaysia Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Philippines Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Vietnam Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Mexico Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Brazil Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Argentina Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Turkey Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Saudi Arabia Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. UAE Oral Hypoglycemic Agents (OHAs) Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. Sales Market Share of Oral Hypoglycemic Agents (OHAs) by Type (2016-2021) Figure 47. Sales Market Share of Oral Hypoglycemic Agents (OHAs) by Application (2016-2021) Figure 48. Sales Market Share of Oral Hypoglycemic Agents (OHAs) by Application in 2020 Figure 49. Revenue Share of Oral Hypoglycemic Agents (OHAs) by Application (2016-2021) Figure 50. Revenue Share of Oral Hypoglycemic Agents (OHAs) by Application in 2020 Figure 51. Manufacturing Cost Structure of Oral Hypoglycemic Agents (OHAs) Figure 52. Manufacturing Process Analysis of Oral Hypoglycemic Agents (OHAs) Figure 53. Oral Hypoglycemic Agents (OHAs) Industrial Chain Analysis Figure 54. Channels of Distribution Figure 55. Distributors Profiles Figure 56. Bottom-up and Top-down Approaches for This Report Figure 57. Data Triangulation Figure 58. Key Executives Interviewed

Pfizer GlaxoSmithKline Bayer Bristol-Myers Squibb Novonordisk Sanofi-Aventis Servier Huadong Medicine Wanbang Biopharmaceuticals Double-Crane Pharmaceutical Guangzhou Pharmaceutical